$DVAX
Market Cap:
$DVAX SEC Filings
| Filing | Filed On |
|---|---|
| FORM 8-K | 29 Mar 2013 |
| 8-K | 21 Mar 2013 |
| 8-K | 01 Mar 2013 |
| FORM 8-K | 01 Mar 2013 |
| 8-K | 26 Feb 2013 |
| 8-K HEPLISAV(TM) CRL | 25 Feb 2013 |
| FORM 8-K | 07 Feb 2013 |
| 8-K | 05 Feb 2013 |
| 8-K | 19 Dec 2012 |
| FORM 8-K | 15 Nov 2012 |
| FORM 8-K 11-2-2012 | 02 Nov 2012 |
| DYNAVAX REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS | 02 Nov 2012 |
| DYNAVAX TO INITIATE PHASE 1 STUDY FOR ASTHMA | 01 Nov 2012 |
| DYNAVAX ANNOUNCES FDA ADVISORY COMMITTEE TO REVIEW HEPLISAV | 28 Aug 2012 |
| MAA ACCEPTANCE | 23 Aug 2012 |
| CHRISTINE R. LARSON APPOINTED AS CFO | 15 Aug 2012 |
| DYNAVAX REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS | 01 Aug 2012 |
| DYNAVAX SUBMITS HEPLISAV(TM) FOR EU MARKETING AUTHORIZATION | 24 Jul 2012 |
| 8-K | 26 Jun 2012 |
| 8-K | 01 Jun 2012 |
